Suppr超能文献

相似文献

1
Inhibition of Melanoma Cell-Intrinsic Tim-3 Stimulates MAPK-Dependent Tumorigenesis.
Cancer Res. 2022 Oct 17;82(20):3774-3784. doi: 10.1158/0008-5472.CAN-22-0970.
2
Combined blockade of Tim-3 and MEK inhibitor enhances the efficacy against melanoma.
Biochem Biophys Res Commun. 2017 Mar 4;484(2):378-384. doi: 10.1016/j.bbrc.2017.01.128. Epub 2017 Jan 26.
3
Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas.
Cancer Immunol Immunother. 2013 Apr;62(4):629-37. doi: 10.1007/s00262-012-1371-9. Epub 2012 Nov 10.
4
Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-κB/IL-6/STAT3 axis.
Oncogene. 2018 May;37(18):2456-2468. doi: 10.1038/s41388-018-0140-4. Epub 2018 Feb 16.
5
Tim-3 mediates T cell trogocytosis to limit antitumor immunity.
J Clin Invest. 2022 May 2;132(9). doi: 10.1172/JCI152864.
7
Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade.
Cancer Immunol Res. 2014 May;2(5):410-22. doi: 10.1158/2326-6066.CIR-13-0171. Epub 2014 Feb 11.
8
Targeting STAT3 Abrogates Tim-3 Upregulation of Adaptive Resistance to PD-1 Blockade on Regulatory T Cells of Melanoma.
Front Immunol. 2021 Apr 15;12:654749. doi: 10.3389/fimmu.2021.654749. eCollection 2021.
10
T Cell CEACAM1-TIM-3 Crosstalk Alleviates Liver Transplant Injury in Mice and Humans.
Gastroenterology. 2023 Nov;165(5):1233-1248.e9. doi: 10.1053/j.gastro.2023.07.004. Epub 2023 Jul 19.

引用本文的文献

1
Galectin-9-An Emerging Glyco-Immune Checkpoint Target for Cancer Therapy.
Int J Mol Sci. 2025 Aug 19;26(16):7998. doi: 10.3390/ijms26167998.
2
TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives.
Mol Biomed. 2025 May 7;6(1):27. doi: 10.1186/s43556-025-00267-6.
7
TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory.
Cancer Cell. 2023 Nov 13;41(11):1911-1926.e8. doi: 10.1016/j.ccell.2023.09.001. Epub 2023 Oct 5.
8
TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors.
Cancer Immunol Immunother. 2023 Nov;72(11):3405-3425. doi: 10.1007/s00262-023-03516-1. Epub 2023 Aug 11.
9
Autoimmunity and Carcinogenesis: Their Relationship under the Umbrella of Autophagy.
Biomedicines. 2023 Apr 8;11(4):1130. doi: 10.3390/biomedicines11041130.
10
T Cell Immunoglobulin and Mucin Domain 3 (TIM-3) in Cutaneous Melanoma: A Narrative Review.
Cancers (Basel). 2023 Mar 10;15(6):1697. doi: 10.3390/cancers15061697.

本文引用的文献

2
Tim-3 finds its place in the cancer immunotherapy landscape.
J Immunother Cancer. 2020 Jun;8(1). doi: 10.1136/jitc-2020-000911.
4
TIM3 comes of age as an inhibitory receptor.
Nat Rev Immunol. 2020 Mar;20(3):173-185. doi: 10.1038/s41577-019-0224-6. Epub 2019 Nov 1.
5
Tumour-intrinsic resistance to immune checkpoint blockade.
Nat Rev Immunol. 2020 Jan;20(1):25-39. doi: 10.1038/s41577-019-0218-4. Epub 2019 Sep 30.
6
BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti-PD-1 Antibody.
Clin Cancer Res. 2018 Jul 15;24(14):3377-3385. doi: 10.1158/1078-0432.CCR-17-1914. Epub 2018 Apr 12.
7
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.
Cell. 2018 Apr 5;173(2):400-416.e11. doi: 10.1016/j.cell.2018.02.052.
8
TIM-3 Regulates CD103 Dendritic Cell Function and Response to Chemotherapy in Breast Cancer.
Cancer Cell. 2018 Jan 8;33(1):60-74.e6. doi: 10.1016/j.ccell.2017.11.019.
9
Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy.
Oncoimmunology. 2017 Nov 9;7(2):e1385690. doi: 10.1080/2162402X.2017.1385690. eCollection 2018.
10
Interferon-γ Signaling in Melanocytes and Melanoma Cells Regulates Expression of CTLA-4.
Cancer Res. 2018 Jan 15;78(2):436-450. doi: 10.1158/0008-5472.CAN-17-1615. Epub 2017 Nov 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验